Drug Trial Radar · NCT05569772
Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes
Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
252
Planned (sponsor's estimate)
Start
Sep 14, 2023
Primary completion
Mar 2030
Study completion May 2030
Sponsor
- Lead sponsor
- Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University Hospital, Antwerp; Universitair Ziekenhuis Brussel; General Hospital Groeninge; Vitaz; Centre Hospitalier Universitaire de Liege; Erasme University Hospital; Centre Hospitalier Mouscron; Jan Yperman Ziekenhuis; AZ Turnhout; AZ Sint-Lucas Brugge; Ziekenhuis aan de Stroom; Onze Lieve Vrouw Hospital
- First posted
- Oct 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Gestational diabetes (GDM) is an important contributor to the increasing prevalence of type 2 diabetes (T2DM). Women with glucose intolerance in early postpartum are a particularly high-risk group with about 50% who will develop T2DM within 5 years after the delivery. Moreover, women with a history of GDM progress more rapidly to T2DM compared to women with similarly elevated glucose levels. Early intervention after the index pregnancy is therefore crucial to prevent T2DM. With the SERENA project, the investigators aim to reduce the risk to develop T2DM with the long-acting GLP-1 agonist semaglutide in women with a recent history of GDM and glucose intolerance in early postpartum.
Conditions
- Glucose Intolerance After a Recent History of Gestational Diabetes
Interventions
Semaglutide Pen InjectorDrug
maintenance dose of 1mg SC once weekly
Semaglutide placeboDrug
maintenance dose of 1mg SC once weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Development of T2DMTime frame: by 160 weeks
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
AZORG
Aalst, Belgium · Recruiting
UZA
Antwerp, Belgium · Recruiting
ZAS
Antwerp, Belgium · Recruiting
AZ St Jan Brugge
Bruges, Belgium · Recruiting
Erasme
Brussels, Belgium · Recruiting
UZ Brussel
Brussels, Belgium · Recruiting
Jan Yperman
Ieper, Belgium · Recruiting
AZ Groeninge Kortrijk
Kortrijk, Belgium · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
CHU de Liège
Liège, Belgium · Recruiting
Centre Hospitalier Mouscron
Mouscron, Belgium · Recruiting
Vitaz
Sint-Niklaas, Belgium · Recruiting
AZ Turnhout
Turnhout, Belgium · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.